Psychedelics are challenging the standard of randomized controlled trials

Reality of Psychedelic Entities

• Major subthread on whether DMT/LSD entities are “external beings” or brain-generated.
• Skeptical side:
  • Hallucinations also occur in fever, alcohol withdrawal, dreams, brain stimulation.
  • No physical evidence of extra entities; would require new physics or a new undetected force.
  • Similar reports across users can be explained by similar brains, shared culture/mythology, and suggestibility.
• More open/agnostic side:
  • Personal experiences feel overwhelmingly “real,” leaving some with residual doubt.
  • Argues it’s premature to rule out non-material entities given current limits of neuroscience and consciousness research.
• Some invoke frameworks like bicameral mind theory, internal family systems, and “talking to the subconscious” rather than literal external beings.

Therapeutic Potential and Risks of Psychedelics

• Multiple commenters report genuine psychological benefits (PTSD, depression, trust issues, alcoholism), often attributed to:
  • Access to new perspectives.
  • Emotional “debug mode.”
  • Internalizing insights rather than learning new facts.
• Others stress serious risks:
  • Triggering earlier onset of schizophrenia in predisposed individuals.
  • Persistent derealization, HPPD, or psychotic breaks.
  • Rare but extreme “dark trips,” especially at very high doses or poor set/setting.
• Emphasis that different psychedelics (LSD, psilocybin, DMT, peyote, MDMA) and doses produce very different profiles.

Placebo Effect, Faith, and Clinical Trials

• Strong agreement that mental-health trials have unusually large placebo responses; hence need for careful controls.
• Placebo described as:
  • Real symptom relief (especially for pain, mood) without fixing underlying pathology.
  • Closely related to expectation, hope, and “magical thinking,” but not limited to religious faith.
• Debate on whether placebo is “just noise” vs a powerful therapeutic tool that should be actively harnessed.
• Nocebo effects (harm from negative expectations) and optimism’s impact on health outcomes are discussed.

RCTs, Psychedelics, and Trial Design

• Core challenge: blinding is hard when participants know they’re tripping; standard double-blind RCT assumptions break.
• Some argue RCT “absolutism” is overdone, especially for fatal diseases; others insist RCTs remain essential to avoid bias and overhyped treatments.
• Suggested mitigations: active placebos (e.g., niacin), different statistical approaches, and considering context/therapy as part of the treatment rather than “noise.”

Transcendence and Meaning

• Several argue that the mystical/transcendent quality of trips may be central to antidepressant effects.
• Linked to broader loss of rituals and meaning in modern life; psychedelics may temporarily restore a sense of awe and purpose, which standard pharmacology often ignores.